ROBINS HARLAN S sold $1.8M of ADPT
ROBINS HARLAN S (Chief Scientific Officer) sold 106,160 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $17.41 ($17.37–$18.01, $1.85M total) across 2 trades over 2026-06-15 to 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price range, and that it was executed under a Rule 10b5-1 plan by the Chief Scientific Officer.
Market read
This provides a concrete insider liquidity datapoint but no new fundamental catalyst for ADPT.
What to watch
Traders may over-weight insider sales; without accompanying buys, guidance, trial updates, or financing news, the filing is unlikely to change valuation assumptions.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
SEC Form 4 shows CSO Robins Harlan S sold 106,160 ADPT shares in open-market trades for ~$1.85M under a 10b5-1 plan.
Likely limited immediate price impact; any reaction would be modest and sentiment-driven rather than fundamental.
The filing is a primary-source insider transaction with defined parameters (10b5-1, open-market, weighted avg ~$17.41). The article provides no new operational/financial catalyst, so impact should be constrained.
Market effects
No sector-level read-across; this is company-specific insider activity only.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale disclosure.
- insiderROBINS HARLAN S
Chief Scientific Officer who sold 106,160 shares in open-market trades under a 10b5-1 plan.